Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5338K Administered Orally in Healthy Adult Males.

Trial Profile

Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5338K Administered Orally in Healthy Adult Males.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2018

At a glance

  • Drugs PXS-5338K (Primary)
  • Indications Hepatic fibrosis; Non-alcoholic steatohepatitis; Pulmonary fibrosis; Renal fibrosis
  • Focus Adverse reactions
  • Sponsors Pharmaxis
  • Most Recent Events

    • 14 Jun 2018 Status changed from not yet recruiting to recruiting, according to a Pharmaxis media release.
    • 14 Jun 2018 According to a Pharmaxis media release, the first stage of this study has been completed and is no entering the final stage where different fixed doses are given for 14 days
    • 13 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top